Falanga A, Bolognese Dalessandro A P, Casali B, Roncaglioni M C, Donati M B
Int J Cancer. 1987 Jun 15;39(6):774-7. doi: 10.1002/ijc.2910390620.
Cancer Procoagulant (CP), a cysteine proteinase which triggers blood coagulation by directly activating Factor X (FX) in the absence of Factor VII (F VII), has recently been isolated from rabbit V2 carcinoma and biochemically characterized. We have studied the procoagulant activity of tissue extracts from 4 murine experimental tumors in order to define whether or not a F VII-independent activity with cysteine proteinase characteristics was present. The tumors studied were: Lewis lung carcinoma (3LL), B16 melanoma (B16), JW sarcoma (JWS) and the M4 variant of the mFS6 fibrosarcoma (M4). Extracts from 3LL, B16 and JWS tumor initiated coagulation in both the presence and absence of F VII, their procoagulant activity was sensitive to iodoacetamide (1 mM) and mercury chloride (0.1 mM). The procoagulant of M4 extract was dependent on the presence of F VII and was not significantly affected by the cysteine proteinase inhibitors. An Ouchterlony double immunodiffusion study showed immunological cross-reactivity of all but M4 extracts to a polyclonal antibody to purified CP. The present study suggests that the procoagulant(s) present in the murine tumors 3LL, B16 and JWS are enzymatically and immunologically indistinguishable from cancer procoagulant of the rabbit V2 carcinoma.
癌促凝剂（CP）是一种半胱氨酸蛋白酶，在缺乏因子VII（F VII）的情况下，通过直接激活因子X（FX）来触发血液凝固。最近已从兔V2癌中分离出该物质并进行了生化特性鉴定。我们研究了4种小鼠实验性肿瘤组织提取物的促凝活性，以确定是否存在具有半胱氨酸蛋白酶特性的不依赖F VII的活性。所研究的肿瘤有：Lewis肺癌（3LL）、B16黑色素瘤（B16）、JW肉瘤（JWS）以及mFS6纤维肉瘤的M4变体（M4）。3LL、B16和JWS肿瘤的提取物在有和没有F VII的情况下均可启动凝血，它们的促凝活性对碘乙酰胺（1 mM）和氯化汞（0.1 mM）敏感。M4提取物的促凝作用依赖于F VII的存在，且不受半胱氨酸蛋白酶抑制剂的显著影响。免疫双扩散研究表明，除M4提取物外，所有提取物与纯化CP的多克隆抗体均有免疫交叉反应。本研究表明，小鼠肿瘤3LL、B16和JWS中存在的促凝剂在酶学和免疫学上与兔V2癌的癌促凝剂无法区分。
